Indivior Pharmaceuticals, Inc. (INDV) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Win.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth No data; EPS growth No data.
26/46
2.8 / 5 stars
All 46 Win/Lose results and 74 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 5 wins, 5 losses, 2 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinINDV / S&P 34.61% / 15.20% |
LoseINDV / S&P 13.46% / 15.00% |
WinINDV / S&P 232.14% / 50.40% |
| 2026-Q10/3 |
LoseINDV / S&P -15.05% / -4.33% |
LoseINDV / S&P 10.25% / 11.30% |
LoseINDV / S&P -9850.00% / 27.70% |
| 2025-Q42/3 |
WinINDV / S&P 48.82% / 2.65% |
LoseINDV / S&P 4.29% / 9.00% |
WinINDV / S&P 3180.00% / 13.40% |
| 2025-Q31/1 |
WinINDV / S&P 63.57% / 8.12% |
No dataINDV / S&P / 4.61% |
No dataINDV / S&P / 13.45% |
| 2025-Q21/1 |
WinINDV / S&P 54.67% / 10.94% |
No dataINDV / S&P / 4.83% |
No dataINDV / S&P / 10.63% |
| 2025-Q10/1 |
LoseINDV / S&P -23.33% / -4.27% |
No dataINDV / S&P / 4.98% |
No dataINDV / S&P / 10.57% |
| 2024-Q41/1 |
WinINDV / S&P 27.49% / 2.41% |
No dataINDV / S&P / 5.25% |
No dataINDV / S&P / 6.15% |
| 2024-Q30/1 |
LoseINDV / S&P -39.52% / 5.89% |
No dataINDV / S&P / 5.89% |
No dataINDV / S&P / 6.11% |
| 2024-Q20/1 |
LoseINDV / S&P -24.74% / 4.28% |
No dataINDV / S&P / 5.38% |
No dataINDV / S&P / 5.12% |
| 2024-Q11/1 |
WinINDV / S&P 40.28% / 10.56% |
No dataINDV / S&P / 5.71% |
No dataINDV / S&P / 5.59% |
| 2023-Q40/1 |
LoseINDV / S&P -33.81% / 11.69% |
No dataINDV / S&P / 6.81% |
No dataINDV / S&P / 7.78% |
| 2023-Q31/1 |
WinINDV / S&P -3.07% / -3.27% |
No dataINDV / S&P / 7.52% |
No dataINDV / S&P / -5.03% |
| 2023-Q21/1 |
WinINDV / S&P 42.00% / 8.74% |
No dataINDV / S&P / 9.50% |
No dataINDV / S&P / -8.57% |
| 2023-Q10/1 |
LoseINDV / S&P -22.94% / 7.50% |
No dataINDV / S&P / 10.77% |
No dataINDV / S&P / -15.69% |
| 2022-Q41/1 |
WinINDV / S&P 45.00% / 7.56% |
No dataINDV / S&P / 11.88% |
No dataINDV / S&P / -17.99% |
| 2022-Q30/1 |
LoseINDV / S&P -18.92% / -4.88% |
No dataINDV / S&P / 13.47% |
No dataINDV / S&P / -1.41% |
| 2022-Q21/1 |
WinINDV / S&P -1.33% / -16.10% |
No dataINDV / S&P / 13.71% |
No dataINDV / S&P / 11.04% |
| 2022-Q11/1 |
WinINDV / S&P 8.70% / -4.60% |
No dataINDV / S&P / 15.97% |
No dataINDV / S&P / 42.23% |
| 2021-Q41/1 |
WinINDV / S&P 18.56% / 11.03% |
No dataINDV / S&P / 15.00% |
No dataINDV / S&P / 96.40% |
| 2021-Q31/1 |
WinINDV / S&P 37.91% / 0.58% |
No dataINDV / S&P / 10.77% |
No dataINDV / S&P / 69.42% |
| 2021-Q21/1 |
WinINDV / S&P 22.32% / 8.55% |
No dataINDV / S&P / 6.58% |
No dataINDV / S&P / 51.81% |
| 2021-Q11/1 |
WinINDV / S&P 17.75% / 6.17% |
No dataINDV / S&P / -1.06% |
No dataINDV / S&P / 7.39% |
| 2020-Q40/1 |
LoseINDV / S&P 4.64% / 12.15% |
No dataINDV / S&P / -3.72% |
No dataINDV / S&P / -33.42% |
| 2020-Q31/1 |
WinINDV / S&P 35.92% / 8.93% |
No dataINDV / S&P / -2.04% |
No dataINDV / S&P / -27.10% |
| 2020-Q21/1 |
WinINDV / S&P 71.67% / 20.54% |
No dataINDV / S&P / -0.46% |
No dataINDV / S&P / -27.11% |
| 2020-Q11/1 |
WinINDV / S&P 15.38% / -19.60% |
No dataINDV / S&P / 3.47% |
No dataINDV / S&P / -14.75% |
| 2019-Q40/1 |
LoseINDV / S&P -9.25% / 9.07% |
No dataINDV / S&P / 5.36% |
No dataINDV / S&P / 2.99% |
| 2019-Q31/1 |
WinINDV / S&P 12.13% / 1.70% |
No dataINDV / S&P / 5.02% |
No dataINDV / S&P / 0.21% |
| 2019-Q20/1 |
LoseINDV / S&P -57.42% / 4.30% |
No dataINDV / S&P / 6.64% |
No dataINDV / S&P / 8.65% |
| 2019-Q10/1 |
LoseINDV / S&P -11.11% / 13.65% |
No dataINDV / S&P / 8.12% |
No dataINDV / S&P / 14.29% |
| 2018-Q40/1 |
LoseINDV / S&P -44.21% / -13.52% |
No dataINDV / S&P / 9.05% |
No dataINDV / S&P / 18.23% |
| 2018-Q30/1 |
LoseINDV / S&P -52.02% / 7.71% |
No dataINDV / S&P / 10.21% |
No dataINDV / S&P / 19.06% |
| 2018-Q20/1 |
LoseINDV / S&P -9.93% / 3.43% |
No dataINDV / S&P / 9.03% |
No dataINDV / S&P / 14.46% |
| 2018-Q11/1 |
WinINDV / S&P 1.84% / -0.76% |
No dataINDV / S&P / 7.68% |
No dataINDV / S&P / 12.46% |
| 2017-Q41/1 |
WinINDV / S&P 23.55% / 6.64% |
No dataINDV / S&P / 7.03% |
No dataINDV / S&P / 13.82% |
| 2017-Q31/1 |
WinINDV / S&P 9.09% / 4.48% |
No dataINDV / S&P / 5.68% |
No dataINDV / S&P / 17.57% |
| 2017-Q20/1 |
LoseINDV / S&P 2.77% / 3.09% |
No dataINDV / S&P / 4.83% |
No dataINDV / S&P / 17.74% |
| 2017-Q11/1 |
WinINDV / S&P 11.83% / 6.07% |
No dataINDV / S&P / 3.67% |
No dataINDV / S&P / 13.32% |
| 2016-Q40/1 |
LoseINDV / S&P -8.74% / 3.82% |
No dataINDV / S&P / 2.09% |
No dataINDV / S&P / 7.05% |
| 2016-Q31/1 |
WinINDV / S&P 18.31% / 3.85% |
No dataINDV / S&P / 0.20% |
No dataINDV / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | INDV total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 45.39% | 20.78% |
| Annualized return | 45.39% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | INDV total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 158.14% | 83.14% |
| Annualized return | 20.88% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | INDV total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 70.94% | 319.30% |
| Annualized return | 5.51% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |